Allarity Therapeutics Aktie

Allarity reports from a phase 2 study that median overall survival under Stenoparib exceeds 25 months; the Kaplan‑Meier analysis was still immature after about 22 months of follow‑up. The data, presented at the AACR conference, exceed the 16–16.5 months seen with more recently approved therapies and are well above the 11.5–13 months typical for chemotherapy. Stenoparib showed favorable safety with reduced myelotoxicity and is active regardless of BRCA status; the drug also received FDA Fast Track designation. Financial figures show a small market capitalization, a current ratio of 2.31, but high cash burn rates and negative EBITDA, while analysts have a price target of $9.00. » Plus sur de.investing.com

Allarity Therapeutics has appointed Jeffrey S. Ervin as its new part-time chief financial officer following the resignation of Alexander Epshinsky. The company is facing financial challenges but reports progress in patent applications, research collaborations, and the advancement of its DRP technology. Additionally, Jesper Høiland has been newly appointed to the board of directors. » Plus sur de.investing.com

Allarity Therapeutics has received acceptance of a patent application in Australia for its Drug Response Predictor (DRP) as a companion diagnostic for Stenoparib. This strengthens the company's international IP protection and advances the development of Stenoparib for cancer treatment. Additionally, Allarity announced a research collaboration and changes to its board of directors. » Plus sur de.investing.com